Home › Companies › ADMA Biologics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and ADMA Biologics, Inc.’s Form 8-K, filed 2026-06-02 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2024-2025 2025-2026
Explore ADMA Biologics, Inc. in the interactive database Compare manager voting policies
These tallies are ADMA Biologics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-02 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Alison C. Finger | 156,849,830 | -- | -- | 19,376,842 | 23,040,875 | Majority: yes |
| Elect Director: Eduardo Rene Salas | 171,947,523 | -- | -- | 4,279,149 | 23,040,875 | Majority: yes |
| Proposal 2: The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and | 198,655,040 | 329,056 | 283,451 | -- | -- | Majority: yes |
| Proposal 3: The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay"). | 168,169,866 | 7,730,690 | 326,116 | -- | 23,040,875 | Majority: yes |
Source: ADMA Biologics, Inc., Form 8-K, filed with the SEC on 2026-06-02 — read the filing on EDGAR.
Each item below shows how the 357 asset managers that disclosed a ADMA Biologics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 9 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
ADMA Biologics, Inc.’s own tally for this item (“Proposal 3: The approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Say-on-Pay").”): 168,169,866 for, 7,730,690 against, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 232,288,977 outstanding shares: 72% for, 3% against (76% of the company cast a for/against vote).
The 356 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 35,671,902 | 3,111 | 0 | 0 | For |
| Vanguard | 22,493,348 | 20 | 2 | 0 | For |
| State Street | 13,534,849 | 0 | 0 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 11,738,761 | 0 | 0 | 0 | For |
| Nuveen | 7,643,330 | 0 | 0 | 0 | For |
| American Century | 7,515,474 | 0 | 0 | 0 | For |
| Fidelity | 6,302,373 | 0 | 0 | 0 | For |
| Invesco | 0 | 5,869,668 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 5,830,605 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,140,191 | 0 | 0 | 0 | For |
| Caligan Partners LP | 4,109,865 | 0 | 0 | 0 | For |
| TIAA | 4,052,144 | 0 | 0 | 0 | For |
| Charles Schwab | 4,028,508 | 0 | 0 | 0 | For |
| B Group, Inc. | 3,198,949 | 0 | 0 | 0 | For |
| Federated Hermes | 3,169,165 | 0 | 0 | 0 | For |
| Putnam | 2,969,685 | 0 | 0 | 0 | For |
| Northern Trust | 2,136,771 | 0 | 0 | 0 | For |
| Ranger Investment Management, L.P. | 2,055,615 | 0 | 0 | 0 | For |
| Dimensional | 1,904,804 | 0 | 0 | 0 | For |
| Fundsmith LLP | 0 | 1,649,493 | 0 | 0 | Against |
| Duquesne Family Office LLC | 1,545,610 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,501,886 | 0 | 0 | 0 | For |
| Point72 | 1,490,651 | 0 | 0 | 0 | For |
| Allspring | 1,421,012 | 0 | 0 | 0 | For |
Showing the 25 largest of 356 asset managers. See all 356 in the interactive database.
Combines 4 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Alison C. Finger”): 156,849,830 for, 19,376,842 withheld, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 232,288,977 outstanding shares: 68% for, 8% withheld (76% of the company cast a for/withheld vote).
The 103 asset managers below cast 100% of the shares they voted on this item FOR (91,621,277 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 25,918,010 | 0 | 427,111 | 0 | For |
| Vanguard | 20,445,936 | 0 | 37,384 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 4,051,804 | 0 | Abstain |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 1,589,164 | 0 | Abstain |
| Nuveen | 0 | 0 | 1,439,853 | 0 | Abstain |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 1,167,273 | 0 | Abstain |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 329,728 | 0 | 187,370 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 489,842 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 364,267 | 0 | Abstain |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Brighthouse | 82,394 | 0 | 250,898 | 0 | Abstain |
| Russell Investments | 0 | 0 | 292,066 | 0 | Abstain |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
ADMA Biologics, Inc.’s own tally for this item (“Elect Director: Eduardo Rene Salas”): 171,947,523 for, 4,279,149 withheld, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 232,288,977 outstanding shares: 74% for, 2% withheld (76% of the company cast a for/withheld vote).
The 103 asset managers below cast 100% of the shares they voted on this item FOR (99,786,889 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,281 | 0 | 39 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 1,589,164 | 0 | Abstain |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 329,728 | 0 | 187,370 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 489,842 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Brighthouse | 82,394 | 0 | 250,898 | 0 | Abstain |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
ADMA Biologics, Inc.’s own tally for this item (“Proposal 2: The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and”): 198,655,040 for, 329,056 against, per its Form 8-K filed 2026-06-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 232,288,977 outstanding shares: 86% for, 0.2% against (86% of the company cast a for/against vote).
The 103 asset managers below cast 99.9% of the shares they voted on this item FOR (101,986,352 for, 2 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 26,345,121 | 0 | 0 | 0 | For |
| Vanguard | 20,483,316 | 2 | 0 | 0 | For |
| Capital Group | 11,738,761 | 0 | 0 | 0 | For |
| State Street | 8,946,809 | 0 | 0 | 0 | For |
| Fidelity | 5,746,339 | 0 | 0 | 0 | For |
| TIAA | 4,051,804 | 0 | 0 | 0 | For |
| American Century | 3,547,215 | 0 | 0 | 0 | For |
| Invesco | 2,561,022 | 0 | 0 | 0 | For |
| Charles Schwab | 1,938,807 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,589,164 | 0 | 0 | 0 | For |
| Nuveen | 1,439,853 | 0 | 0 | 0 | For |
| Federated Hermes | 1,320,457 | 0 | 0 | 0 | For |
| Dimensional | 1,299,905 | 0 | 0 | 0 | For |
| Putnam | 1,167,273 | 0 | 0 | 0 | For |
| Allspring | 688,578 | 0 | 0 | 0 | For |
| Jackson National | 537,981 | 0 | 0 | 0 | For |
| Equitable | 517,098 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 495,279 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 489,842 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 375,073 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,267 | 0 | 0 | 0 | For |
| World Funds Trust | 350,000 | 0 | 0 | 0 | For |
| First Trust | 348,223 | 0 | 0 | 0 | For |
| Brighthouse | 284,727 | 0 | 48,565 | 0 | For |
| Russell Investments | 292,066 | 0 | 0 | 0 | For |
Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.
Ranked by the number of ADMA Biologics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 232,288,977 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 15.36% |
| 2 | Vanguard | 9.68% |
| 3 | State Street | 5.83% |
| 4 | Capital Group | 5.05% |
| 5 | Capital Research Global Investors | 5.05% |
| 6 | Nuveen | 3.29% |
| 7 | American Century | 3.24% |
| 8 | Fidelity | 2.71% |
| 9 | Invesco | 2.53% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 15.86% | 13F |
| Vanguard Group | 8.98% | 13F |
| State Street | 6.06% | 13F |
| Citadel Advisors | 2.69% | 13F |
| Dimensional Fund Advisors | 2.15% | 13F |
| Invesco | 1.77% | 13F |
| Point72 | 1.42% | 13F |
| Goldman Sachs | 1.21% | 13F |
Percentages above are of 232,288,977 shares outstanding, as reported by ADMA Biologics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADMA Biologics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At ADMA Biologics, Inc.'s shareholder meeting held 2026-06-02, in the 2025-2026 proxy season, 357 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,738 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ADMA Biologics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-02.
ADMA Biologics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).